The role of cytokines in the initiation and progression of myelofibrosis

被引：126
作者：
Hasselbalch, Hans C. [1 ]
机构：
[1] Roskilde Hosp Univ Copenhagen, Dept Hematol, DK-4000 Roskilde, Denmark
来源：
CYTOKINE & GROWTH FACTOR REVIEWS | 2013年 / 24卷 / 02期
关键词：
Cytokines; Myeloproliferative neoplasms; Myelofibrosis; Chronic inflammation; Interferon-alpha2; JAK-inhibitor; Statins; RECOMBINANT INTERFERON-ALPHA; QUALITY-OF-LIFE; CHRONIC MYELOPROLIFERATIVE NEOPLASMS; PAN-DEACETYLASE INHIBITOR; TYROSINE KINASE JAK2; NF-KAPPA-B; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; BONE-MARROW; GROWTH-FACTOR;
D O I：
10.1016/j.cytogfr.2013.01.004
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms. Abnormal expression and activity of a number of proinflammatory cytokines are associated with MF, in which immune dysregulation is pronounced as evidenced by dysregulation of several immune and inflammation genes. The discovery of the Janus kinase 2 (JAK2) V617F mutation has led to the development of a number of JAK1/2 inhibitors in the treatment of MF and similar neoplasms. Here, the role of cytokines in MF initiation and progression is discussed, the impact of current therapies is reviewed, and new combination therapies are proposed, such as JAK1/2 inhibitors with interferons, statins, and epigenetic modifiers for patients with MF and related neoplasms. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：133 / 145
页数：13
相关论文
共 171 条
  • [1] Adamson R, 2009, J Wound Care, V18, P349
  • [2] Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    Alchalby, Haefaa
    Badbaran, Anita
    Zabelina, Tatjana
    Kobbe, Guido
    Hahn, Joachim
    Wolff, Daniel
    Bornhaeuser, Martin
    Thiede, Christian
    Baurmann, Herrad
    Bethge, Wolfgang
    Hildebrandt, York
    Bacher, Ulrike
    Fehse, Boris
    Zander, Axel R.
    Kroeger, Nicolaus
    [J]. BLOOD, 2010, 116 (18) : 3572 - 3581
  • [3] TYPE-I INTERFERONS ARE POTENT INHIBITORS OF INTERLEUKIN-8 PRODUCTION IN HEMATOPOIETIC AND BONE-MARROW STROMAL CELLS
    AMAN, MJ
    RUDOLF, G
    GOLDSCHMITT, J
    AULITZKY, WE
    LAM, C
    HUBER, C
    PESCHEL, C
    [J]. BLOOD, 1993, 82 (08) : 2371 - 2378
  • [4] Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
    Aoki, Y
    Feldman, GM
    Tosato, G
    [J]. BLOOD, 2003, 101 (04) : 1535 - 1542
  • [5] DIVERGENT IN-VIVO AND IN-VITRO ANTILEUKEMIC ACTIVITY OF RECOMBINANT INTERFERON-BETA IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA
    AULITZKY, WE
    PESCHEL, C
    DESPRES, D
    AMAN, J
    TRAUTMAN, P
    TILG, H
    RUDOLF, G
    HUTTMANN, H
    OBERMEIER, J
    HEROLD, M
    HUBER, C
    [J]. ANNALS OF HEMATOLOGY, 1993, 67 (05) : 205 - 211
  • [6] Contribution of bone microenvironment to leukemogenesis and leukemia progression
    Ayala, F.
    Dewar, R.
    Kieran, M.
    Kalluri, R.
    [J]. LEUKEMIA, 2009, 23 (12) : 2233 - 2241
  • [7] Improved Efficacy Upon Combined JAK1/2 and Pan-Deacetylase Inhibition Using Ruxolitinib (INC424) and Panobinostat (LBH589) in Preclinical Mouse Models of JAK2V617F-Driven Disease
    Baffert, Fabienne
    Evrot, Emeline
    Ebel, Nicolas
    Roelli, Claudia
    Andraos, Rita
    Qian, Zhiyan
    Romanet, Vincent
    Murakami, Masato
    Radimerski, Thomas
    [J]. BLOOD, 2011, 118 (21) : 363 - 363
  • [8] Therapeutic approaches in myelofibrosis
    Barosi, Giovanni
    Rosti, Vittorio
    Vannucchi, Alessandro M.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1597 - 1611
  • [9] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [10] MPL mutations in myeloproliferative disorders:: analysis of the PT-1 cohort
    Beer, Philip A.
    Campbell, Peter J.
    Scott, Linda M.
    Bench, Anthony J.
    Erber, Wendy N.
    Bareford, David
    Wilkins, Bridget S.
    Reilly, John T.
    Hasselbalch, Hans C.
    Bowman, Richard
    Wheatley, Keith
    Buck, Georgina
    Harrison, Claire N.
    Green, Anthony R.
    [J]. BLOOD, 2008, 112 (01) : 141 - 149
12345678910